28 results
8-K
EX-99.1
LBPH
Longboard Pharmaceuticals, Inc.
1 Aug 24
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
4:10pm
for their collaboration along the way. We look forward to sharing trial design and details of our highly anticipated global Phase 3 program at an R&D Day
8-K
EX-99.2
LBPH
Longboard Pharmaceuticals, Inc.
1 Aug 24
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
4:10pm
As of July 30, 2024 Second Quarter 2024 Operating Expenses $25.6 million R&D - $20.4 million G&A - $5.2 million As of June 30, 2024 Key Milestones
8-K
EX-99.2
th1jx
12 Mar 24
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
4:10pm
8-K
EX-99.1
nmmpolpxlhly
29 Nov 23
Regulation FD Disclosure
8:35am
8-K
EX-99.1
i0y1enyrm lp
3 Nov 22
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results
8:46am
8-K
EX-99.1
gjfsrn
4 Aug 22
Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results
4:19pm
8-K
EX-99.1
v6wv1
5 May 22
Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results
12:00am
10-K
l7fqypoz0teks060dedi
3 Mar 22
Annual report
4:31pm
8-K
EX-99.1
7t0ine2j
3 Mar 22
Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results
4:16pm
8-K
EX-99.1
ngfuv3zyw9 2zhh
10 Jan 22
Regulation FD Disclosure
7:01am
8-K
EX-99.1
q99ne
1 Dec 21
Regulation FD Disclosure
9:01am